AIM: We studied the prevalence of resistance mutations in drug-naïve HIV-infected individuals at the Bela-Bela treatment site to gather information on the presence of antiretroviral (ARV) drug-resistant viruses in drug-naïve populations, so as to improve treatment guidance. SUBJECTS AND METHODS: Drug-naïve HIV-l1-infected individuals were sequentially recruited between February 2008 and December 2008 from individuals visiting the voluntary counselling and testing (VCT) services of the Bela-Bela HIV/AIDS Wellness Clinic. Viral subtyping was done by phylogenetic analysis; drug-resistant mutations were determined according to the Stanford HIV Drug Resistance Interpretation and the International AIDS Society-USA Guidelines. RESULTS: A drug-resistant mutation prevalence of 3.5% (95% confidence interval 0.019796-0.119077) comprising Y181C and L33F was observed; 98% of the viruses were HIV-1 subtype C on the protease (PR) and reverse transcriptase (RT) gene regions. CONCLUSION: The prevalence of drug-resistant mutations in drug-naïve persons may be low in Bela-Bela after 8 years of access to antiretroviral treatment (ART), and resistance testing before initiating treatment may not be needed.
AIM: We studied the prevalence of resistance mutations in drug-naïve HIV-infected individuals at the Bela-Bela treatment site to gather information on the presence of antiretroviral (ARV) drug-resistant viruses in drug-naïve populations, so as to improve treatment guidance. SUBJECTS AND METHODS: Drug-naïve HIV-l1-infected individuals were sequentially recruited between February 2008 and December 2008 from individuals visiting the voluntary counselling and testing (VCT) services of the Bela-Bela HIV/AIDS Wellness Clinic. Viral subtyping was done by phylogenetic analysis; drug-resistant mutations were determined according to the Stanford HIV Drug Resistance Interpretation and the International AIDS Society-USA Guidelines. RESULTS: A drug-resistant mutation prevalence of 3.5% (95% confidence interval 0.019796-0.119077) comprising Y181C and L33F was observed; 98% of the viruses were HIV-1 subtype C on the protease (PR) and reverse transcriptase (RT) gene regions. CONCLUSION: The prevalence of drug-resistant mutations in drug-naïve persons may be low in Bela-Bela after 8 years of access to antiretroviral treatment (ART), and resistance testing before initiating treatment may not be needed.
Authors: Ann M Dennis; Joshua T Herbeck; Andrew L Brown; Paul Kellam; Tulio de Oliveira; Deenan Pillay; Christophe Fraser; Myron S Cohen Journal: J Acquir Immune Defic Syndr Date: 2014-10-01 Impact factor: 3.731
Authors: Benjamin Chimukangara; Richard J Lessells; Soo-Yon Rhee; Jennifer Giandhari; Ayesha B M Kharsany; Kogieleum Naidoo; Lara Lewis; Cherie Cawood; David Khanyile; Kassahun A Ayalew; Karidia Diallo; Reshmi Samuel; Gillian Hunt; Alain Vandormael; Babill Stray-Pedersen; Michelle Gordon; Tariro Makadzange; Photini Kiepiela; Gita Ramjee; Johanna Ledwaba; Monalisa Kalimashe; Lynn Morris; Urvi M Parikh; John W Mellors; Robert W Shafer; David Katzenstein; Pravi Moodley; Ravindra K Gupta; Deenan Pillay; Salim S Abdool Karim; Tulio de Oliveira Journal: EClinicalMedicine Date: 2019-03-18
Authors: Justen Manasa; Siva Danaviah; Sureshnee Pillay; Prevashinee Padayachee; Hloniphile Mthiyane; Charity Mkhize; Richard John Lessells; Christopher Seebregts; Tobias F Rinke de Wit; Johannes Viljoen; David Katzenstein; Tulio De Oliveira Journal: J Vis Exp Date: 2014-03-30 Impact factor: 1.355
Authors: Mary F Kearney; Jonathan Spindler; Ann Wiegand; Wei Shao; Richard Haubrich; Sharon Riddler; Christina M Lalama; Michael D Hughes; John M Coffin; John W Mellors Journal: PLoS One Date: 2018-01-25 Impact factor: 3.240